Nevertheless, the combination blockade of IDO1 and PD‐1/PD‐L1 might be more appropriate for inflamed tumors, given that the driving factor for IDO1 expression in NSCLC patients is likely inflammation rather than the tumor itself.108. This evidence concerns the gene IDO1 and neoplasm.